Description
On 19 February 2007, the first meeting between UNSW, University of Melbourne, National ICT Australia, the Bionic Ear Institute, and the Centre for Eye Research Australia was held to discuss bionic eye research. These parties later formed the consortium Bionic Vision Australia (BVA), which officially launched in 2010. The business plan was finalised in October 2008 with consultancy firm SPP and put to the Prime Minister Kevin Rudd on 5 November 2008. The first Board meeting was held on 30 March 2010. Professor Emeritus David Penington AC served as the first Chair of the Board from 2010 to 2013. He was succeeded by Professor Mark Hargreaves. Professor Anthony N. Burkitt served as Director for the duration of BVA. The National Vision Research Institute, the Australian National University, the University of Western Sydney and the Royal Victorian Eye and Ear Hospital were variously supporting, participating, or project partners. The aim was to develop a functional retinal prosthesis or “bionic eye” capable of restoring vision to people with vision impairment due to retinitis pigmentosa and age-related macular degeneration. The assembled team comprised experts in the fields of ophthalmology, biomedical engineering, electrical engineering, materials science, neuroscience, vision science, psychophysics, wireless integrated-circuit design, and surgical, preclinical and clinical practice. UNSW was a key player in the consortium, developing the first advanced prototype, and leading the consortium’s commercialisation activities through NewSouth Innovations and the company Bionic Vision Technologies Pty Ltd (BVT). The University of Melbourne was designated Administering Organisation for the grant, with the Executive team based in the Melbourne School of Engineering. In December 2009, BVA secured funding through a four-year, $42 million grant administered by the Australian Research Council (ARC), effective from 1 January 2010. The funds were made available through a Special Research Initiative in Bionic Vision Science and Technology established by the Australian Government. In July 2013, ARC offered another year of funding to BVA. BVA’s ARC funding period ended at the end of 2014. There was enough capital to extend the consortium, continue efforts to commercialise through BVT, and perform National Health and Medical Research Council-funded trials in 2015. BVA was ultimately wound up in 2016. Although initially in financial jeopardy, BVT secured funding and continued commercial operations. Controlling Organisation: UNSW - 01/10/08 - 31/12/2016